Explore our materials

10th APACC 2025

DEBATE: Long-acting Injectables Should Replace Oral Antiretrovirals for Biomedical HIV Prevention in the Asia-Pacific Region - APACC 2025

Moderator: Annette Sohn, MD, PhD - TREAT Asia/amfAR, Thailand. Pro Standpoint: Community Perspective Jennifer Ho, MEd - Global Health Advocate, Thailand. Con Standpoint: Clinical Perspective Rayner Kay Jin Tan, PhD - Saw Swee Hock School Of Public Health, National University Of Singapore, Singapore. Pro Standpoint: Clinical Perspective Nagalingeswaran Kumarasamy, MD, FRCP, PhD - Voluntary Health Services, Infectious Diseases Medical Centre, India, Con Standpoint: Community Perspective Danvic Rosadiño, DIH - LoveYourself Inc., Philippines.

10th APACC 2025

Abstract #39 Data from the Positive Perspectives 3 Study Highlights the Continued Need for Expansion of Awareness, Belief and Confidence in Undetectable Equals Untransmittable (U=U) - Kota Iwashashi

10th APACC 2025

Abstract #38 Building Inclusive Healthcare: Tackling HIV-Related Stigma and Discrimination in Malaysian Primary Care Clinics - Khalidah Maruan

10th APACC 2025

Abstract #37 Low Levels of Awareness of Undetectable=Untransmittable among MSM in Five Asian Countries: Results from the Asia Pacific MSM Internet Survey - Curtis Chan

10th APACC 2025

Abstract #35 Efficacy and Safety of Ainuovirine Plus Lamivudine, and Tenofovir DF in Young People with HIV-1: Pooled Analyses of RACER, and SPRINT Studies - Two Randomized, Active-Controlled Phase 3 Trials -Fujie Zhang

10th APACC 2025

Abstract #34 Week 96 Results from Dolutegravir/ Lamivudine Versus Bictegravir/ Emtricitabine/Tenofovir Alafenamide Fumarate: Real-World Assessment of Weight Gain in People Living with HIV of Asian OrigiN (DRAGON) - Chien-Yu Cheng

10th APACC 2025

Abstract #33 Twelve-Month (12M) Effectiveness and Safety of Bictegravir/Emtricitabine/ Tenofovir Alafenamide (B/F/TAF) in Treatment-Experienced People with HIV: A Pooled Analysis from Observational Cohort Studies Across Asia - Rumi Minami

10th APACC 2025

Abstract #36 Phase 3/3b Experience With Long-Acting Cabotegravir and Rilpivirine: Efficacy, Safety, and Virologic Outcomes Beyond 124 Weeks in Participants Identifying as Asian - Jun Yong Choi

10th APACC 2025

Abstract #32 Informing the Design of Future PrEP Strategies for MSM in Taiwan: A Bayesian Discrete Choice Experiment Analysis - Joyce Huei-Jiuan Wu

10th APACC 2025

Abstract #31 Expanding Access to Oral HIV Pre-Exposure Prophylaxis (PrEP): Implementation Outcomes of a Pharmacy-Led PrEP Service Delivery Model in Malaysia - Yan Nee Gan

10th APACC 2025

Abstract #30 Improving Mental Health of People Living with HIV Through a Community-Based Antiretroviral Delivery: A Quasi-Experimental Study in Cambodia - Sovannary Tuot

10th APACC 2025

Abstract #29 Cost-Effectiveness of Rapid Versus Delayed ART Initiation in Japan: A Markov Modeling Analysis - Toshibumi Taniguchi